Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Centessa Pharmaceuticals (CNTA) EBITDA Margin (2022 - 2025)

Historic EBITDA Margin for Centessa Pharmaceuticals (CNTA) over the last 3 years, with Q1 2025 value amounting to 188.49%.

  • Centessa Pharmaceuticals' EBITDA Margin changed N/A to 188.49% in Q1 2025 from the same period last year, while for Sep 2025 it was 1614.62%, marking a year-over-year decrease of 78383200.0%. This contributed to the annual value of 2161.02% for FY2023, which is N/A changed from last year.
  • As of Q1 2025, Centessa Pharmaceuticals' EBITDA Margin stood at 188.49%.
  • Centessa Pharmaceuticals' EBITDA Margin's 5-year high stood at 3979.73% during Q2 2022, with a 5-year trough of 188.49% in Q1 2025.
  • Over the past 3 years, Centessa Pharmaceuticals' median EBITDA Margin value was 1950.75% (recorded in 2022), while the average stood at 2029.36%.
  • Over the last 5 years, Centessa Pharmaceuticals' EBITDA Margin had its largest YoY gain of -5451800bps in 2023, and its largest YoY loss of -30270400bps in 2023.
  • Over the past 3 years, Centessa Pharmaceuticals' EBITDA Margin (Quarter) stood at 1950.75% in 2022, then fell by -28bps to 1405.56% in 2023, then plummeted by -113bps to 188.49% in 2025.
  • Its EBITDA Margin stands at 188.49% for Q1 2025, versus 1405.56% for Q4 2023 and 1527.55% for Q3 2023.